Abbott
ABBOTT PARK, Ill., March 28, 2011 /PRNewswire/ -- Abbott announced today that it has introduced a Micro-Implantation Cataract Suite designed to help improve cataract procedure outcomes and safety.
The Micro-Implantation Cataract Suite, featured at the American Society of Cataract and Refractive Surgery Symposium and Congress in San Diego, enables the surgeon to perform an entire micro-surgical procedure, which can reduce surgically induced astigmatism, provide a safer intra-operative environment, and promote faster healing and visual recovery.
This advanced form of cataract surgery is performed using a micro-incision, which is smaller and therefore may provide added patient safety. During the procedure, the cataract is removed through the micro-incision, and a foldable intraocular lens (IOL) is inserted into the eye.
"The launch of Abbott's Micro-Implantation Cataract Suite represents another key advancement toward better patient outcomes in cataract surgery," said Roger Steinert, M.D., chairman of ophthalmology, University of California, Irvine. "The combined benefits of Abbott's market-leading products are even more prominent now that they are delivered throughout a complete micro-implantation procedure."
The Micro-implantation Cataract Suite consists of five separate components, each designed to maximize the benefits of the micro-implantation procedure. The components include:
About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at www.abbott.com.
CONTACT: Media, Steve Chesterman, +1-714-247-8711, or Financial, Tina
Ventura, +1-847-935-9390, both for Abbott
Web site: http://www.abbott.com/